Skip to content

Clinical trials

Phase 1/2 trials in Bangladesh

Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.

Filters: Phase: Phase 1/2 Country / region: Bangladesh Clear all

24 trials match Source: ClinicalTrials.gov registrations

Trials started per year

By phase, 2000 to 2026.

Trials started per year
CategoryTrials
20041
20061
20081
20092
20112
20122
20153
20162
20181
20192
20211
20221
20242
20252
20261

Status

Trials by registry status. Select a bar to filter.

Trials by status
CategoryTrials
Completed15
Unknown status4
Recruiting2
Active, not recruiting1
Not yet recruiting1
Terminated1

Top lead sponsors

A sponsor with a page on Pharma Observatory links to it.

Top lead sponsors
CategoryTrials
International Centre for Diarrhoeal Disease Research, Bangladesh9
Bangabandhu Sheikh Mujib Medical University, Dhaka, Bangladesh2
PATH2
Replicor Inc.2
Bangladesh Laser & Cell Surgery Institute & Hospital1
Clinical Research Organization, Dhaka, Bangladesh1
Globe Biotech Limited1
Johns Hopkins Bloomberg School of Public Health1
MSD Wellcome Trust Hilleman Laboratories Pvt. Ltd.1
National Institute of Neurosciences and Hospital, Dhaka1

Top conditions

MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.

Top conditions
CategoryTrials
Hepatitis B, Chronic3
Cholera2
Typhoid Fever2
Carcinoma, Hepatocellular1
Dengue1
Diarrhea1
Escherichia coli Infections1
Hand, Foot and Mouth Disease1
Henipavirus Infections1
Pneumococcal Infections1

Trials

Showing 51 to 24 of 24. Each trial links to its page on Pharma Observatory.

No trials match these filters.

Try a different keyword, or clear a filter.

Recently changed trials

Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.

No changes to these trials in the last 7 days.

Go deeper on Pharma Observatory

Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.